Precigen Inc
PGENHealthcare|Biotechnology|USA
$5.33
-0.21 (-3.80%)
Tangible Book
$0.01
Financials
Financial Snapshot
Market Cap
$1.90B
Enterprise Value
$-42.0M
Revenue (TTM)
$31.6M
Net Income (TTM)
$-204.4M
Cash & Equivalents
—
Net Cash/Share
$-0.17
Free Cash Flow (TTM)
$-117.0M
Operating CF (TTM)
$-115.3M
Debt/Equity
4.86
Cash Runway & Burn Rate
Cash on Hand
$0.00
Quarterly Burn
$28.8M
Monthly Burn
$9.6M
Est. Runway
—
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $237.2M | $79.7M | $216.9M | $75.1M | $100.1M | $108.7M | $56.0M | $62.9M | $97.9M | $97.9M | $56.2M | |
| Operating Cash Flow | $-49.0M | $-103.7M | $-124.2M | $-77.0M | $-77.0M | $-55.8M | $-65.0M | $-66.9M | $-68.2M | $-87.8M | $-115.3M | |
| Free Cash Flow | $-80.6M | $-150.4M | $-165.8M | $-84.5M | $-84.5M | $-63.0M | $-70.0M | $-68.5M | $-76.8M | $-89.8M | $-117.0M | |
| Capital Expenditure | $-31.6M | $-46.7M | $-41.6M | $-7.5M | $-7.5M | $-7.2M | $-4.9M | $-1.5M | $-8.6M | $-2.0M | $-1.6M | |
| Financing Cash Flow | $12.1M | $4.3M | $309.8M | $32.7M | $32.7M | $121.2M | $-155.3M | $29.6M | $110.6M | $90.0M | $90.8M |
R&D Spending
R&D (TTM)
$36.5M
R&D Intensity
115.5%
R&D Growth YoY
-11.7%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $190.9M | $219.5M | $151.2M | $32.0M | $103.2M | $14.3M | $26.9M | $6.2M | $3.9M | $9.7M | $31.6M | |
| R&D Expense | $112.1M | $109.2M | $333.0M | $39.4M | $41.6M | $47.9M | $47.2M | $48.6M | $53.1M | $41.3M | $36.5M | |
| R&D % of Revenue | 58.7% | 49.7% | 220.3% | 123.2% | 40.4% | 336.0% | 175.3% | 780.9% | 1352.1% | 426.8% | 115.5% | |
| SG&A | $142.3M | $130.7M | $125.2M | $72.7M | $91.7M | $52.0M | $48.0M | $40.4M | $41.3M | $70.1M | $78.8M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $190.9M | $219.5M | $151.2M | $32.0M | $103.2M | $14.3M | $26.9M | $6.2M | $3.9M | $9.7M | $31.6M | |
| Cost of Goods Sold | $61.6M | $61.7M | $62.7M | $5.4M | $55.5M | $5.7M | $6.3M | $6.1M | $4.3M | $4.8M | $6.3M | |
| Gross Profit | $129.3M | $157.8M | $88.5M | $26.6M | $47.7M | $8.5M | $20.6M | $106.0K | $-342.0K | $4.9M | $25.3M | |
| R&D | $112.1M | $109.2M | $333.0M | $39.4M | $41.6M | $47.9M | $47.2M | $48.6M | $53.1M | $41.3M | $36.5M | |
| SG&A | $142.3M | $130.7M | $125.2M | $72.7M | $91.7M | $52.0M | $48.0M | $40.4M | $41.3M | $70.1M | $78.8M | |
| Operating Income | $-125.2M | $-82.1M | $-369.7M | $-85.5M | $-85.7M | $-91.4M | $-74.6M | $-88.9M | $-94.7M | $-106.6M | $-90.0M | |
| Interest Expense | $-861.0K | $-584.0K | $-8.5M | $-18.2M | $-18.4M | $-18.8M | $-6.8M | $-468.0K | $-6.0K | $-3.9M | $-6.8M | |
| Pretax Income | $-194.2M | $-78.4M | $-395.9M | $-104.5M | $-103.9M | $-111.0M | $-80.0M | $-96.4M | $-128.0M | $-250.6M | $-204.4M | |
| Net Income | $-186.6M | $-117.0M | $-509.3M | $-170.5M | $-170.5M | $-92.2M | $28.3M | $-95.9M | $-126.2M | $-250.6M | $-204.4M | |
| EPS (Diluted) | -1.58 | -0.98 | -3.93 | -1.02 | -1.02 | -0.47 | 0.14 | -0.39 | -0.47 | -1.37 | -1.18 | |
| EBITDA | $-168.7M | $-46.6M | $-354.3M | $-68.8M | $-67.9M | $-78.5M | $-62.4M | $-89.2M | $-123.5M | $-243.6M | $-194.0M | |
| Shares Out. (M) | 117.98 | 120.00 | 129.52 | 167.07 | 167.07 | 197.76 | 200.36 | 244.54 | 267.73 | 312.98 | 354.29 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $62.6M | $68.1M | $96.9M | $65.8M | $51.8M | $36.4M | $4.9M | $7.6M | $29.5M | $30.2M | $7.5M | |
| Marketable Securities | $174.6M | $11.6M | $120.0M | $9.3M | $48.3M | $72.2M | $51.1M | $55.3M | $68.4M | $67.6M | $48.8M | |
| Total Current Assets | $315.2M | $154.0M | $285.5M | $234.6M | $148.9M | $156.6M | $118.2M | $68.8M | $102.4M | $115.2M | $101.7M | |
| Total Assets | $949.1M | $846.9M | $716.2M | $455.8M | $314.6M | $359.9M | $216.0M | $151.0M | $145.3M | $155.5M | $138.6M | |
| Total Current Liabilities | $94.6M | $80.2M | $61.6M | $122.9M | $42.1M | $34.6M | $78.6M | $23.0M | $21.5M | $37.3M | $21.1M | |
| Long-Term Debt | $7.6M | $7.5M | $211.2M | $186.3M | $171.5M | $179.9M | $0.00 | $0.00 | $0.00 | $93.2M | $93.5M | |
| Total Liabilities | $379.8M | $300.3M | $337.5M | $384.1M | $247.4M | $252.5M | $89.7M | $32.5M | $106.8M | $134.6M | $118.4M | |
| Stockholders' Equity | $560.2M | $533.6M | $362.9M | $71.7M | $67.2M | $107.3M | $126.3M | $118.5M | $38.5M | $20.9M | $20.2M | |
| Retained Earnings | $-729.3M | $-847.8M | $-1.33B | $-1.65B | $-1.82B | $-1.92B | $-1.87B | $-1.96B | $-2.09B | $-2.34B | $-2.35B |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $-49.0M | $-103.7M | $-124.2M | $-77.0M | $-77.0M | $-55.8M | $-65.0M | $-66.9M | $-68.2M | $-87.8M | $-115.3M | |
| Capital Expenditure | $-31.6M | $-46.7M | $-41.6M | $-7.5M | $-7.5M | $-7.2M | $-4.9M | $-1.5M | $-8.6M | $-2.0M | $-1.6M | |
| Free Cash Flow | $-80.6M | $-150.4M | $-165.8M | $-84.5M | $-84.5M | $-63.0M | $-70.0M | $-68.5M | $-76.8M | $-89.8M | $-117.0M | |
| Investing Cash Flow | $-28.4M | $104.3M | $-151.2M | $27.8M | $27.8M | $-74.5M | $226.4M | $-3.1M | $-20.7M | $-1.5M | $25.9M | |
| Financing Cash Flow | $12.1M | $4.3M | $309.8M | $32.7M | $32.7M | $121.2M | $-155.3M | $29.6M | $110.6M | $90.0M | $90.8M | |
| Issuance of Stock | $0.00 | $13.7M | $88.0M | $35.0M | $35.0M | $121.0M | $0.00 | $72.8M | $31.2M | $0.00 | $0.00 | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $-1.7M | $-1.3M | |
| Issuance of Debt | $5.6M | $6.2M | $224.4M | $10.4M | $10.0M | $0.00 | $0.00 | $0.00 | $0.00 | $92.8M | $-654.0K | |
| Payments of Debt | $-6.0M | $-7.0M | $-5.0M | $-12.8M | $-12.4M | $-466.0K | $-155.3M | $-43.2M | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $53.0M | $52.7M | $36.3M | $18.4M | $18.4M | $13.9M | $10.2M | $9.9M | $9.5M | $10.9M | $11.2M | |
| Net Change in Cash | $-66.2M | $6.0M | $34.6M | $-16.2M | $-16.2M | $-8.9M | $5.3M | $-40.7M | $21.7M | $717.0K | $1.4M |
Dilution Tracker
Shares outstanding grew 79.2% over 5 years — significant dilution
Shares Outstanding
354M
5-Year Share Growth
+79.2%
Stock Issuance (TTM)
$0.00
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 117.98 | 120.00 | 129.52 | 167.07 | 167.07 | 197.76 | 200.36 | 244.54 | 267.73 | 312.98 | 354.29 | |
| YoY Change % | — | 1.7% | 7.9% | 29.0% | 0.0% | 18.4% | 1.3% | 22.0% | 9.5% | 16.9% | 13.2% | |
| Stock Issuance | $0.00 | $13.7M | $88.0M | $35.0M | $35.0M | $121.0M | $0.00 | $72.8M | $31.2M | $0.00 | $0.00 | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $-1.7M | $-1.3M | |
| Stock Based Comp. | $53.0M | $52.7M | $36.3M | $18.4M | $18.4M | $13.9M | $10.2M | $9.9M | $9.5M | $10.9M | $11.2M |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 67.7% | 71.9% | 58.5% | 83.2% | 46.2% | 59.7% | 76.4% | 1.7% | -8.7% | 50.2% | 80.1% | |
| Operating Margin % | -65.6% | -37.4% | -244.5% | -267.3% | -83.0% | -640.7% | -277.3% | -1428.5% | -2412.9% | -1100.8% | -284.9% | |
| Net Margin % | -97.7% | -53.3% | -336.9% | -533.0% | -165.3% | -646.0% | 105.2% | -1540.6% | -3216.2% | -2588.2% | -647.0% | |
| EBITDA Margin % | -88.4% | -21.3% | -234.4% | -215.1% | -65.8% | -549.9% | -232.0% | -1433.3% | -3146.4% | -2515.2% | -613.9% | |
| FCF Margin % | -42.2% | -68.5% | -109.7% | -264.3% | -81.9% | -441.7% | -260.0% | -1099.9% | -1955.6% | -927.6% | -370.2% | |
| ROE % | -29.8% | -21.4% | -113.6% | -78.5% | -245.6% | -105.6% | 24.2% | -78.4% | -160.8% | -843.6% | -3176.7% | |
| ROA % | -19.3% | -13.0% | -65.2% | -29.1% | -44.3% | -27.3% | 9.8% | -52.3% | -85.2% | -166.7% | -146.8% | |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - | - |
Valuation
P/E (TTM)At Loss
HistoricalAt Loss / 9.93 / 17.67
Industry Med.27.51
P/S57.88
Historical4.09 / 14.46 / 300.67
Industry Med.9.49
P/B93.42
Historical1.40 / 4.55 / 102.81
Industry Med.2.93
EV/EBITDA-10.00
Historical-956.43 / -7.35 / -1.20
Industry Med.13.02
EV/Revenue61.42
Historical4.48 / 15.95 / 295.47
Industry Med.8.59
P/FCF—
Historical78.22 / 85.10 / 95.00
Industry Med.27.13
Intrinsic Value Models
Tangible Book
$0.01
Median P/S Value
$1.25
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PE Ratio | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | 10.86 | At Loss | At Loss | At Loss | At Loss | |
| PS Ratio | 14.87 | 6.30 | 5.60 | 28.69 | 16.50 | 51.53 | 11.34 | 53.60 | 74.67 | 134.84 | 57.88 | |
| PB Ratio | 5.10 | 2.64 | 2.88 | 12.48 | 28.49 | 7.15 | 2.50 | 2.82 | 8.48 | 70.85 | 93.42 | |
| EV/EBITDA | -15.63 | -28.90 | -2.99 | -15.30 | -29.38 | -10.81 | -5.00 | -3.11 | -1.91 | -6.08 | -10.00 | |
| EV/Revenue | 13.81 | 6.14 | 7.00 | 32.89 | 19.35 | 59.47 | 11.59 | 44.63 | 60.03 | 152.81 | 61.42 |
Analyst Estimates & Quality
Altman Z-Score
-17.88
Distress
Piotroski F-Score
4
Moderate
Beneish M-Score
4.75
Possible Manipulator
Forward Estimates
| Metric | Current Year | Next Year | 2 Years Out |
|---|---|---|---|
| Revenue | $124.43M | $229.03M | $437.53M |
| Net Income | $-9.08M | $75.14M | $278.27M |
| EPS | -0.03 | 0.20 | 0.72 |
| Book Value per Share | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow per Share | -0.05 | 0.21 | 0.00 |
| Operating CF | $-17.72M | $74.40M | $0.00M |
Dividends
Revenue Segments
By Business
| Segment | 2025 |
|---|---|
| Single segment | $9.7M |
By Geography
| Segment | 2025 |
|---|---|
| United States | $9.7M |